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Abstract
Health Issue: The average age of natural menopause in Western societies is estimated to be 51
years; women in Canada can therefore expect to live, on average, a third of their lives in post-
menopausal years. During these years women are at increased risk of chronic diseases such as
osteoporosis and cardiovascular disease.
Key Findings: Clinical and epidemiological data on women in perimenopause are limited. There
are no adequate Canadian data on symptom severity and prevalence among perimenopausal and
postmenopausal women. Scientific evidence is lacking to support or refute claims that commonly
used botanical products can offer therapeutic relief of menopausal symptoms.
Recent data from the Women's Health Initiative suggest that combined estrogen plus therapy
increases the risk of stroke, coronary artery disease and breast cancer. Hormone therapy is no
longer recommended for the prevention of chronic diseases for asymptomatic women. Stroke is
an important issue for perimenopausal and postmenopausal women and sex differences may exist
in the progestin treatment of stroke. Osteoporosis affects an estimated one in six women over the
age of 50.
Data Gaps and Recommendations: There is a need to conduct clinical and epidemiological
research aimed at better understanding the menopausal transition and defining its clinical phases.
Investigations aimed at alternative combinations and doses of hormone therapy and non-
pharmaceutical alternatives in light of known risks and benefits are also necessary. Health care
practitioners and women need to be educated on the risks and effective treatment related to
cardiovascular disease so they can present for treatment more quickly and receive the most
effective therapies.
Background
The perimenopausal phase of a woman's life can span sev-
eral years. The changes that occur during this period of
transition will affect women to varying degrees. For some
women these changes can give rise to symptoms that are
severe and disruptive, and for others symptoms are mild
and the transition is welcomed. Clinical and epidemio-
logical data on women in perimenopause are limited, and
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what data there are come primarily from Caucasian pop-
ulations. Somewhat greater attention has been given to
post-menopausal women's health, and these data are
often extrapolated to women in perimenopause. The aver-
age age of natural menopause in Western societies is esti-
mated to be 51 years; women in Canada can therefore
expect to live, on average, a third of their lives in post-
menopausal years. During these years women are at
increased risk of chronic diseases such as osteoporosis and
cardiovascular disease.
Methods
Menopause touches on a number of health issues, which
are addressed separately in this chapter. For some of them
new data were analyzed, and for others a review of the cur-
rent knowledge is presented, in part because of the lack of
menopause data in large, national surveys. Literature
reviews were conducted through several databases,
including MEDLINE, PREMEDLINE, PsycINFO, and
EMBASE. Meta-analyses of studies published in languages
other than English were included. In the case of alterna-
tive therapies, a search was done for on-line resources
housed at national and international health organization
web sites.
For stroke, mortality data were obtained from the Cana-
dian Mortality Database at Health Canada on individuals
aged 20 and older for whom stroke was listed as the
underlying cause of death (ICD codes 431, 434, 436).
Rates were age-standardized to the 1991 Canadian popu-
lation. Hospital admission rates for stroke were obtained
from the Canadian Morbidity Database at the Canadian
Institute for Health Information. Cases were included if
they were treated at an acute care hospital and had a diag-
nosis of stroke (ICD-9 codes 431, 434, 436). Subsequent
admissions in the time period could not be identified and
were not excluded. Geographic breakdowns reflect the
province of hospitalization.
Information on cardiovascular disease has been supple-
mented by data from the FASTRAK® II clinical registry,
which collects quantitative and qualitative data on demo-
graphic characteristics, treatments and outcomes of all
patients with acute coronary syndrome during their stay at
participating Canadian hospitals. The registry includes all
cardiac patients to minimize patient selection and was
specifically designed to include hospitals without a tradi-
tion of participating in clinical trials in an effort to mini-
mize hospital selection. In addition, clinical data
elements are captured. Data are processed at the FAS-
TRAK® II Data Management Centre, based in the Cardiol-
ogy Department of a major teaching hospital. These data
were used to demonstrate practice patterns for reperfusion
therapies in this setting. All female patients in the registry
who had an ST elevation myocardial infarction during the
period January 1, 2001, to December 31, 2001, were
included. Data on 1,489 female patients were available
for analysis
Results
Perimenopause
Natural menopause is defined as the permanent cessation
of menstruation resulting from the loss of ovarian follicu-
lar activity. It is confirmed after 12 consecutive months of
amenorrhea in the absence of other pathological or phys-
iological causes, given that a woman who has experienced
12 months without flow has a 5% or lower chance of fur-
ther flow.[1] Natural menopause, by this definition, can
be known with certainty only in retrospect. There is cur-
rently no single biological marker to identify when a
woman has reached menopause.[2] Perimenopause is
defined by the World Health Organization and the North
American Menopause Society as the two to eight years pre-
ceding menopause and one year following final
menses.[1,3]
The average age at menopause is 51 years for Caucasian
women in Western societies. Studies have reported differ-
ences in age at menopause (earlier or later) by race or
country, but findings are not consistent. Studies in devel-
oping countries generally report younger age at meno-
pause, but this is likely due to methodological differences.
Factors that may affect age of menopause are not well
understood, although smoking has been consistently
related to earlier age at menopause by one to two years.
There is a great deal that is yet to be understood about per-
imenopause and women's experiences of this period of
transition. Studies of menopausal symptoms are prob-
lematic, given that it is difficult to accurately identify
when women enter the perimenopausal phase. Temporal
associations between menopause and what may be men-
opausal symptoms cannot be assessed using cross-sec-
tional studies. There have been a few good longitudinal
studies that have looked at the perimenopausal transition,
[4-7] including one in Manitoba. National data on symp-
tom prevalence are not available.
A majority of women will experience menstrual changes
years before their final period. Only an estimated 10%
report an abrupt cessation. Heavy flow is common and,
among women in the Manitoba study, led to medical con-
sultation by about 25% of women.[6] Some women expe-
rience acute perimenopausal symptoms. The most
commonly reported are vasomotor symptoms (hot
flushes and night sweats), vaginal dryness, mastalgia,
sleep disturbances, urinary incontinence, changes in
libido, mood changes and fatigue. The prevalence of
many of these symptoms varies from early to late peri-
menopause. Vasomotor symptoms, though they are notBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
Page 3 of 14
(page number not for citation purposes)
unique to menopause, are by far the most commonly
reported. In studies of Caucasian populations, up to 85%
of Caucasian women report vasomotor symptoms, and
these women are more likely to report other physical and
emotional symptoms. There is great variation among
countries in the proportion of women reporting hot
flushes. Estimates within countries also vary widely. Stud-
ies of Asian populations tend to report the lowest rates.[8]
Studies in Thailand and Japan have reported rates of 6%
and 12% respectively, and studies in Africa have reported
rates of 30% to 80%.[8] Truly comparable studies in non-
Caucasian populations are lacking.
There is some debate as to which of these symptoms can
be attributed directly to hormonal fluctuations and which
cannot. Short-term hormone therapy, traditionally used
for the management of menopausal symptoms, has been
shown to be more effective than placebo only in the treat-
ment of vasomotor symptoms, sleep disturbances and
genitourinary symptoms.[9,10] The experience of other
symptoms requires further attention.
Psychiatric Disorders in Perimenopause and Menopause
Contrary to widely held beliefs, menopause is not associ-
ated with an increase in psychiatric disorders, although
the perimenopausal period may be. In one of the first
studies of menopausal symptomology, Neugarten and
Kraines found an increase in somatic but not in psycho-
logical complaints at menopause.[11] Multiple commu-
nity studies have since indicated no increase in the
prevalence of psychiatric disorders after meno-
pause.[6,12-16] On the other hand, some studies do sug-
gest a higher prevalence of psychiatric morbidity among
perimenopausal women, especially those seeking care in
menopause clinics.[17,18] Studies have found no relation
between menopausal status and symptoms such as
insomnia, fatigue and depression, although they have
noted an increase in somatic symptoms at meno-
pause.[11,19] There does, however, seem to be an increase
in psychiatric symptoms, including depression, anxiety
and psychosomatic symptoms, in the years immediately
preceding the complete cessation of menses.[20] A prior
history of depression has been noted to be associated with
depressive and other psychological symptoms in
perimenopause.[21]
Women who become depressed during the perimeno-
pause may be reacting to one or a combination of factors.
Alterations in the levels of reproductive hormones may
directly affect central neurotransmitter activity and con-
tribute to a dysregulation of the hypothalamic-pituitary-
adrenal axes, leading to the onset of depression in vulner-
able women.[13] Women with histories of depression,
especially occurring at times of hormonal change such as
premenstrually or postpartum, may be particularly vul-
nerable. [16,22,23] For some women, the hormone-sensi-
tive physical complaints such as night sweats and hot
flushes result in discomfort, irritability and low self-
esteem that can be confused with major depressive disor-
ders. Psychosocial stressors may also play a role. Changes
in family roles, loss of fertility and fear of aging with its
ensuing loss of physical attractiveness, usefulness and sta-
tus in the community can lead to depression.[24] Lifestyle
issues such as smoking and stress also appear to be related
to symptoms of depression.[14,25]
For menopausal women experiencing mild depression as
well as anxiety, insomnia and vasomotor symptoms, ovar-
ian hormone therapy is a first-line treatment unless there
are contraindications to estrogen use.[26] Amelioration of
the physical symptoms may lead to an increase in well-
being. In women with moderate to severe depression or
anxiety, antidepressant medication is the treatment of
choice and the use of estrogen in such cases remains con-
troversial.[27,28] Studies using estrogen to treat major
depression have yielded mixed results.[29,30] The use of
unopposed estrogen is contraindicated in women with
intact uteruses. The addition of progesterone has been
associated with a worsening of mood.[29,31] The role of
ovarian hormone therapy in augmenting the effects of
antidepressants is still unclear.[32,33]
More research is needed to clarify the effects of using hor-
mones in the treatment of menopausal women. Educa-
tional programs are also important to give correct
information to perimenopausal women and debunk
myths that may contribute to depression and low self-
esteem at this time of life.[24,34] Women should be
directed to some of the Web sites that provide women-
centred lay information in order to further reduce their
fears and misconceptions about the menopause. These
include the Web sites for Menstrual Cycle Research http:/
/www.pop.psu.edu/smcr, National Women's Health Net-
work http://www.nwhn.org/, Dr. Susan Love http://
www.susanlove.com/community_flash_A_frames.html,
and the Centre for Menstrual Cycle and Ovulation
Research http://www.cemcor.ubc.ca.
Alternative Therapies
For a variety of reasons, women appear to be taking a
greater interest in alternative therapies for treatment of
menopausal symptoms. Despite what appears to be an
increasing prevalence in use among Canadian women,
very little has been published with respect to efficacy, side
effects or the pharmacokinetic features of botanical
products.
With the exception of black cohosh, scientific evidence is
lacking about whether commonly used botanical prod-
ucts are effective for the treatment of menopausal symp-BMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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toms. Red clover (Trifolium pratense) is a source of a large
number of phytoestrogens (isoflavones) and has shown
estrogenic activity in a number of studies; however, it has
not been shown to decrease symptoms significantly more
then placebo. Chasteberry (Vitex agnus-castus), dong quai
(Angelica sinensis), Asian ginseng (Panax ginseng), North
American ginseng (Panax quinquefolius), licorice (Glycyr-
rhiza glabra) and evening primrose (Oenothera biennis) are
also used for the management of menopausal symptoms,
but without evidence of their effectiveness. Studies have
shown chasteberry to be effective in treating mastalgia and
premenstrual syndrome.
A number of clinical trials, mostly German, have found
that black cohosh (Cimicifuga racemosa) relieves perimen-
opausal symptoms, including hot flushes and depressed
mood. Black cohosh may decrease hot flushes by 25% as
compared with placebo.[35]. It has been approved for use
in Germany by the Special Expert Committee of the Ger-
man Federal Institute for Drugs and Medical Devices
(Commission E). Phase I and phase II clinical trials are
currently under way in the United States.
Many of the studies reported in the literature have been of
short duration. Often an effect is observed but is similar to
that seen for placebo over the short period of follow-up. It
is not clear whether this relation would hold true over a
longer period. Recent studies have found estrogenic activ-
ity in a number of botanical products commonly used for
the treatment of menopausal symptoms, suggesting a
potential for their use and a viable mechanism of
action.[36]
Soy products, rich in phytoestrogens (isoflavones), have
the potential to provide an exogenous source of estrogen,
and the lower rates of vasomotor symptoms reported in
Asian populations are sometimes attributed to greater soy
intake. Data from studies considering the relation of soy,
or isoflavones, to vasomotor symptoms are inconclusive.
Studies in post-menopausal women, however, have
shown a favourable effect on lipid levels.[2,36]
Other alternative therapies for which there is some evi-
dence to suggest a decrease in vasomotor symptoms
include relaxation, mind-body or yoga breathing strate-
gies.[37,38] As well, topical or transdermal use of proges-
terone was shown in a controlled trial to decrease
vasomotor symptoms in menopausal women.[39]
Hormone Therapy
Hormone therapy (HT), or what has been known as hor-
mone replacement therapy (HRT), is a term that describes
a variety of regimens involving different estrogens and
progestins. Those involving only estrogen therapy are
mainly used for women without a uterus, and those
involving a combination of estrogen plus progestin are for
those with a uterus, since unopposed estrogen (or estro-
gen alone) increases the risk of endometrial cancer.[40]
HT has been used for decades in the treatment of hot
flushes and vaginal dryness. Over the past decade, there
has been significant interest in its use for long-term pre-
vention of chronic diseases, such as cardiovascular dis-
ease, cancer, osteoporosis and memory loss.
Observational studies examining long-term hormone use
have noted a slight increase in incidence of breast cancer
among hormone users compared with non-users and a
decrease in cardiovascular disease.[41] However, recent
results from the Women's Health Initiative show an
increase in both cardiovascular disease and breast can-
cer.[42] The reason for the differences in these findings
requires further exploration.
The Women's Health Initiative (WHI) is a multi-centre,
randomized trial across the United States examining a
variety of factors that may affect post-menopausal health.
It is the most expensive study funded by the National
Institutes of Health in its history and involves 160,000
post-menopausal women.[5] One arm of this study was a
randomized, double-blind placebo-controlled trial
involving 16,608 post-menopausal women, which exam-
ined the use of combined estrogen plus progestin taken
orally every day, as compared with placebo.[42] The study
was terminated early because the risks outweighed the
benefits. After an average of 5.2 years of follow-up, there
was a 26% increase in breast cancer, a 29% increase in cor-
onary heart disease and a 41% increase in stroke among
hormone users. There was, however, a 34% decrease in
hip fractures and a 37% decrease in colorectal cancers.
In light of these results, many scientific bodies (including
the Society of Obstetricians and Gynaecologists of Can-
ada,[43] the American College of Obstetricians and Gyne-
cologists,[44] the North American Menopause
Society,[45] the U.S. Preventive Services Task Force[46]
and the Canadian Task Force on Preventive Health
Care[47]) decided that HT, especially taken in this regi-
men, does not fit the profile of a compound for the pre-
vention of diseases and have thus changed their
recommendations. All are recommending that use of HT
in post-menopausal women should be limited to the
treatment of perimenopausal symptoms, the dose should
be as low as possible, the duration should be as short as
possible, and the use of HT should be evaluated periodi-
cally by the woman and her health care provider. These
scientific bodies are also recommending against using HT
for the prevention of cardiovascular diseases or as first-
line therapy for the prevention and treatment of
osteoporosis in asymptomatic women. The Food and
Drug Administration in the United States has recently
instituted a policy to include these warnings on all HTBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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packaging, whether it is oral or transdermal, estrogen only
or combined estrogen plus progestin.
Despite being the largest trial on HT to date, many ques-
tions remain unanswered. The issue of whether estrogen
alone has similar effects will be addressed by an arm of the
WHI that is continuing and involves 10,000 post-meno-
pausal women. However, the trial results so far have made
research on the use of HT for long-term prevention of
chronic diseases much more difficult to conduct. Two fur-
ther analyses were published recently from the WHI
showing no difference in cognition with estrogen plus
progestin therapy,[48] and if anything, HT may increase
the risk of dementia in women 65 and over.[49] Further-
more, another analysis showed HT made no difference in
quality of life in women without vasomotor symp-
toms.[50] These findings, coupled with previously
reported WHI data, support the conclusion that the risks
of estrogen plus progestin outweigh the benefits.
Osteoporosis
Osteoporosis affects an estimated one in six women and
one in sixteen men over the age of 50.[51] Risk factors are
similar for men and women, but women experience a
higher incidence of fracture, likely because of a higher
prevalence of risk factors. Post-menopausal women in
particular are at increased risk. In the first five years imme-
diately after menopause, women can experience bone loss
at a rate of 2% to5% per year. This rate of bone loss usu-
ally diminishes after about ten years, to 1% to 2% per
year.
The most significant implications associated with oste-
oporosis are complications from fragility fractures. Oste-
oporosis is asymptomatic until a fracture occurs.
Osteoporotic fractures, particularly of the hip and spine,
cause considerable morbidity and mortality. For an aver-
age 50-year-old woman, the lifetime risk of a forearm frac-
ture is 16%, of a spine fracture is 15.6%, of a hip fracture
is 17.5% and of any osteoporotic fracture is more than
40%.[52] Fractures can lead to chronic pain and spinal
deformity. As many as 20% of hip fracture patients will
die in their first year after the fracture, often because of
complications due to hospitalization[53]. Many will lose
their independence and require long-term care. Men show
higher rates of mortality than women following hip frac-
ture. Whether the decrease in survival can be attributed to
fractures or to comorbid illnesses is controversial.
Risk factors for osteoporotic fracture include a prior oste-
oporotic fracture, increasing age, low bone mineral den-
sity (BMD) and a family history of osteoporotic fracture.
Other factors that may also contribute to fracture risk but
may be correlated with BMD include low body weight
(BMI < 20–25 kg/m2), high caffeine intake, smoking, low
physical activity and low calcium intake.
A relation between BMD and fracture risk has been
observed in a number of studies, and BMD remains the
best quantifiable skeletal predictor of osteoporotic frac-
ture for those who have not had a fragility fracture. The
standard classification for osteoporosis and osteopenia is
based on the 1993 WHO criteria,[54] which compare
BMD to a reference population of post-menopausal Cau-
casian women. Using the WHO criteria, a BMD value
greater than or equal to 2.5 standard deviations below the
young adult mean is defined as osteoporosis, and a BMD
value between 1 and 2.5 standard deviations below is
defined as osteopenia. Women with osteopenia have a
lower risk of fracture than women with osteoporosis, but
they may be at greater risk than women with normal bone
mineral density. The Canadian Multicentre Osteoporosis
Study estimates the prevalence of osteoporosis to be
15.8% among women and 6.6% among men over the age
of 50.[51] The prevalence of osteopenia among women
aged 50 and over in Canada is 45.9%.[51] This is very sim-
ilar to the 50% prevalence rate observed in the National
Health and Nutrition Examination Survey III study in the
United States.
Because osteoporotic fractures often result in loss of inde-
pendence and decreased quality of life, the burden they
place on women, their social supports and the health care
system is substantial. An understanding of factors that
contribute to fractures and strategies to prevent falls are
important, especially in decreasing hip fractures among
the elderly. Prevention and treatment can be started early
in women at high risk of fracture. Preventive strategies cur-
rently include lifestyle modifications; ensuring adequate
dietary calcium and vitamin D intake; and several phar-
macological treatment options, including bisphospho-
nates, selective estrogen receptor modulators and, in
selected cases, parathyroid hormone, calcitonin and HT.
Weight-bearing exercise can increase peak bone mass in
teenagers and help maintain bone mass in post-menopau-
sal women.
Stroke
Stroke is the fourth leading cause of death and a leading
cause of disability in Canadian women.[55,56] Major risk
factors for stroke include atrial fibrillation, hypertension,
diabetes mellitus, smoking and hyperlipidemia. The prev-
alence of risk factors for stroke is similar among women
and men, although women over the age of 45 are more
likely to have a diagnosis of hypertension.[56] Smoking is
more common among men than women in every age
group except those under 20 years.[56]BMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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Stroke admissions, mortality and length of stay were cal-
culated for Canadian women and men using data from
the Canadian Institute for Health Information and ICD-9
codes 431, 434 and 436. In 2000, overall hospitalization
rates for stroke were lower among women than men (713
versus 955 per 100,000), but in the older age groups were
higher among women (2,038 women versus 1,942 men
per 100,000 aged over 75). In addition, since stroke risks
increase with age and since women are overrepresented in
the older age groups, the actual number of women with
stroke is higher than the number of men. In Canada in
2000, for example, there were 10,592 women admitted
with stroke, compared with 9,816 men. There were some
variations in stroke admission rates across the country
(Figure 1).
Stroke mortality rates in Canada tend to be lower among
women than men in every age group. In 1997, for exam-
ple, for people aged 65 to 74 years, the mortality rate from
cerebral infarction was 55.69/100,000 among women as
compared with 95.87/100,000 among men. However,
because of the greater proportion of women in the older
age groups, in which stroke mortality is highest, stroke
accounts for more deaths in women than in men (9,375
women versus 6,673 men in 1997) and a higher propor-
tion of all deaths (9% among women versus 5.9% among
men).[56] Stroke mortality rates vary across Canada (Fig-
ures 2 and 3).
Women who experience stroke are often widowed, are less
likely to have social supports, and are more likely to be
discharged to long-term care facilities after stroke.[57]
Stroke admissions tend to be longer and more costly for
women than for men ($32,000 versus $23,000 per
admission).[57]
Secondary stroke prevention includes antiplatelet agents,
anticoagulants for atrial fibrillation, and carotid endarter-
ectomy for carotid stenosis. Canadian data suggest that
sex differences exist in the secondary prevention of stroke.
For example, older women (aged over 85) are less likely
than men to be prescribed antiplatelet agents.[58] In addi-
tion, Canadian women are about half as likely as men to
undergo carotid endarterectomy, even after adjustment
for age.[57,59]
Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of
death in Canadian women.[55,56] In general, major risk
factors for CVD include hypertension, dyslipidemia, dia-
betes mellitus, smoking, inactivity, male sex and older
age. According to the National Population Health Survey
1996–1997 analyses published in The Changing Face of
Heart Disease and Stroke in Canada (2000),[56] many of
the major risk factors have similar prevalence among men
and women. However, more women are likely to have
hypertension, and more men than women are likely to
have diabetes mellitus and to be smokers.
While CVD has been well accepted as a prominent condi-
tion in men, there has been some controversy about the
signs and symptoms, diagnosis and treatment of CVD in
women. It is under-appreciated that women may present
with a broader range of signs and symptoms of heart dis-
ease than men.[60,61] Sex differences have been found in
the management of CVD. Physicians pursue a less aggres-
sive management approach to CVD for women, who
receive fewer referrals for diagnostic and revascularization
procedures and are under-treated with effective medica-
tions. [62-66]
Preferential prescribing for males has also been uncovered
for evidence-based therapies, Canada and the United
States showing similar patterns. In a cohort of 2,070 post-
myocardial infarction (MI) patients from Alberta and
Nova Scotia followed from 1987 to 1992, women not
only had a significantly lower rate of prescription for Aspi-
rin (69% versus 79%), beta-blockers (36% versus 48%)
and thrombolytic agents (20% versus 30%), but also a
higher mortality rate than their male counterparts (18%
versus 12%).[67] Several other studies in North America
throughout the 1990s support these findings of differen-
tial prescribing according to sex in the treatment of cardi-
ovascular disease. [68-71]
This is of particular concern, since the beneficial effects of
therapy for acute coronary syndromes – such as fibrinolyt-
ics, acetylsalicylic acid (ASA), beta-blockers and angi-
otensin-converting enzyme inhibitors – appear to be
equally effective in women as in men. [72-74] Many of
these studies includeonly about 25% of women as partic-
ipants, but the benefits of therapy are of a similar magni-
tudeas in men.
More recently, Haddad and colleagues studied a small
group of 717 MI patients in Nova Scotia to assess their
medical management and found that there were few dif-
ferences in prescribing patterns between men and
women.[75] Previous sex differences may be decreasing,
but ineffective or potentially harmful therapies are still
being preferentially given to women. Most recently, the
Institute for Clinical Evaluative Sciences (ICES) in Ontario
assessed the use of medication in older post-MI patients
(65+ years) over the period of 1994–1995 to 1996–1997
and found few sex-related differences in treatment
rates.[76] Overall, there was room for improvement in the
use of evidence-based therapies in both sexes. However,
there was a 4% to 5% higher rate of use of calcium chan-
nel blockers among women aged 65 to 74 and 75 to 84
years as compared with men. This class of drug has notBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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Age and Sex-Specific Stroke Admission Rates in Canada by Province and Territory, 2000–2001. Figure 1
Age and Sex-Specific Stroke Admission Rates in Canada by Province and Territory, 2000–2001. Source: Canadian 
Institute for Health Information, Hospital Morbidity DatabaseBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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Age and Sex-Specific Intracerebral Haemorrhage Mortality Rates per 100,000 in Canada by Province and Territory, 1997–1998 Figure 2
Age and Sex-Specific Intracerebral Haemorrhage Mortality Rates per 100,000 in Canada by Province and Ter-
ritory, 1997–1998 Source: Health Canada, Canadian Mortality DatabaseBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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Age and Sex-Specific Cerebral Infarction Mortality Rates per 100,000 in Canada by Province and Territory, 1997–1998 Figure 3
Age and Sex-Specific Cerebral Infarction Mortality Rates per 100,000 in Canada by Province and Territory, 
1997–1998 Source: Health Canada, Canadian Mortality DatabaseBMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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been shown to improve mortality after MI and in some
case may increase mortality. In other studies, women have
received more nitrates and calcium channel blockers,
despite the fact that these drugs have not been shown to
decrease mortality.[77,78] In a study assessing whether
evidence changes practice, using the uptake of the land-
mark 4S statin trial into practice as the example, the
increase in the rate of statin therapy among women was
1.6-fold lower than that among men (p = 0.006). This
study indicates a lag in the use of evidence-based therapies
– in this case, statins – in older women in Ontario.[79]
The FASTRAK II database of acute cardiac hospital admis-
sions across Canada for the year 2001 was used to deter-
mine more recent trends by sex in the presentation of
acute myocardial infarction (AMI) and use of acute thera-
pies. There were 4,897 patients with AMI in 2001, 3,365
(69.3%) of whom were male and 1,489 (30.7%) of whom
were female. Figure 4 summarizes the AMI data for
females, and Figure 5 summarizes the data for men.
Women take longer than men to present to hospital after
the start of their symptoms and are more ill upon presen-
tation (Killip class). Fewer women in the younger age
groups (< 55 years and 55 to 64 years) appear to receive
reperfusion therapy with either fibrinolysis or primary
angioplasty. Fewer women in the older age groups (65 to
74 years and over 75 years) receive primary angioplasty. In
all age categories, women have a longer time from arrival
to receipt of fibrinolysis. The target goal of door-to-needle
time of under 30 minutes is reached in 48.5% of men ver-
sus only 38.8% of women. While the numbers are small,
more women than men have strokes and major bleeding,
and the rate of death in hospital at 48 hours after admis-
sion is higher among women across allage categories.
These data show that women present later and are more ill
at presentation, are treated less often and later with
fibrinolysis and angioplasty, and have more complica-
tions of their AMI and its treatment.
Sex differences in prescribing patterns for congestive heart
failure have not been consistent, but they tend to be less
than those found in the multitude of studies evaluating
AMI.[80,81] In an ICES analysis of older patients with
congestive heart failure in Ontario from 1994–1995 to
1996–1997, no sex-related differences were found in the
rates of use of ACE inhibitors.[76] One Canadian study,
which assessed the use of thromboembolic prophylaxis in
3,575 patients with atrial fibrillation from 12 hospitals
during the period 1993–1994, found that significantly
more females received ASA or no treatment as compared
with men. Warfarin was the drug of choice for atrial fibril-
lation in this study.[82] It is possible that some elderly,
frail women may have contraindications that prevent
them from receiving the more effective therapy, warfarin.
Greater awareness and reduction of risk factors for cardio-
vascular disease in women are needed. While preventive
medications are being used more frequently in women,
greater use of effective therapies and less use of ineffective
or potentially harmful ones are warranted.
Summary of Results
• Clinical and epidemiologic data on women in perimen-
opause are limited. There do not appear to be adequate
Canadian data on symptom severity and prevalence
among perimenopausal and post-menopausal women.
Existing data on age at menopause and experience of the
menopausal transition come primarily from Caucasian
populations.
• Perimenopausal and post-menopausal women differ
hormonally and experientially. Therapies tested on one
population should not necessarily be extrapolated to the
other.
• Scientific evidence is lacking to support or refute claims
that commonly used botanical products can offer
therapeutic relief of menopausal symptoms. There are
inadequate data on the efficacy, side effects and pharma-
cokinetic features of these products. However, recent stud-
ies of botanical products commonly used for treatment of
menopausal symptoms have demonstrated estrogenic
activity, suggesting a potential for their use and a viable
mechanism of action.
• Recent data from the Women's Health Initiative suggest
that combination HT increases the risk of stroke, coronary
artery disease and breast cancer. The study did demon-
strate a decrease in risk of colon cancer and hip fracture,
but no difference in cognition or quality of life in asymp-
tomatic women. Thus, combination HT is no longer rec-
ommended for prevention of chronic diseases in
asymptomatic women.
• Sex differences may exist in the secondary prevention of
stroke, and there may be evidence to suggest differential
prescribing for CVD according to sex.
• Stroke is an important issue for women, particularly
those in the older age groups. Women may be less likely
than men to receive antiplatelet agents and carotid endar-
terectomy for secondary stroke prevention, although fur-
ther research is needed to determine whether this is due to
sex alone, to age or to other clinical factors.
• Women are at greater risk of osteoporosis and oste-
oporotic fractures than men. However, women have lower
in-hospital mortality rates than men following hip
fracture.BMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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• Psychiatric disorders are not significantly increased
among menopausal women, although there is some
increase in psychiatric symptoms in the perimenopause.
Discussion
Recommendations
• Conduct clinical and epidemiologic research aimed at
better understanding the menopausal transition and
defining its clinical phases. In order to collect data on per-
imenopausal women, we must be able to identify them.
Use of Reperfusion Therapy in Women with ST Elevation Acute Myocardial Infarction in Canada, January 1, 2001 to December  31, 2001 Figure 4
Use of Reperfusion Therapy in Women with ST Elevation Acute Myocardial Infarction in Canada, January 1, 
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Age is often used as a surrogate for menopausal status,
making it difficult to differentiate conditions that may be
due to biological changes from those that may be attrib-
uted to other factors.
• Investigate alternative combinations and dosing of hor-
mone therapy, in light of known risks and benefits, with
respect to treatment of menopausal symptoms and long-
term outcomes.
Use of Reperfusion Therapy in Men with ST Elevation Acute Myocardial Infarction in Canada, January 1, 2001 to December 31,  2001 Figure 5
Use of Reperfusion Therapy in Men with ST Elevation Acute Myocardial Infarction in Canada, January 1, 2001 
to December 31, 2001. Source: FASTRAK®11 Clinical Registry, 2001BMC Women's Health 2004, 4:S23 http://www.biomedcentral.com/1472-6874/4/S1/S23
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• Investigate non-pharmacological alternatives (risks and
benefits) for the treatment of menopausal symptoms, par-
ticularly those alternatives already in common use.
• Educate health care practitioners and women about the
risks and effective treatments related toCVD so that
women may present for treatment more quickly and
receive the most effective therapies.
• Investigate the use of ovarian hormones to augment the
effect of antidepressants in menopausal women.
Note
Views expressed in this report do not necessarily represent
the views of the Canadian Population Health Initiative,
the Canadian Institute for Health Information or Health
Canada.
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